Early Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

For people with B-ALL (a type of blood cancer affecting B cells):

• People aged 3 to 70 years old
• People who have been diagnosed with B-ALL confirmed through laboratory testing, following recognised medical guidelines
• People whose B-ALL has come back or has not responded to treatment, meeting at least one of these conditions: the cancer did not go into remission after standard chemotherapy; remission lasted less than 12 months after the first round of treatment; one or more follow-up treatments have not worked; or the cancer has relapsed two or more times
• People whose bone marrow testing shows a certain level of abnormal cells above a set threshold (confirm with trial site)
• People who test negative for the Philadelphia chromosome, or who test positive but cannot tolerate or have not responded to two targeted therapies called TKI treatments

For people with B-NHL (a type of lymphoma affecting B cells):

• People aged 18 to 75 years old
• People who have been diagnosed with specific types of B-NHL — including DLBCL, follicular lymphoma, DLBCL transformed from CLL/SLL, PMBCL, or HGBCL — confirmed through laboratory testing using recognised classification guidelines
• People whose B-NHL has come back or has not responded to treatment, meeting at least one of these conditions: the cancer did not respond to or came back after two or more lines of chemotherapy; the cancer showed primary resistance to treatment; or the cancer relapsed after a stem cell transplant using the person's own cells
• People who have at least one measurable area of disease that can be assessed using standard imaging criteria

For all participants (both B-ALL and B-NHL):

• People who have confirmed or strongly suspected involvement of the cancer in the central nervous system (brain and spinal cord)
• People whose liver and kidney function test results fall within the ranges required by the trial (confirm with trial site)
• People whose heart scan shows the heart pumping at 50% efficiency or above
• People with no active lung infection and whose blood oxygen level in normal indoor air is at least 92%
• People whose expected survival is at least 3 months
• People who are functioning reasonably well in daily life, based on a standard medical scale scoring 0 to 2 (confirm with trial site)
• People, or their legal guardians, who agree to take part and sign a consent form

Who may not be able to join:

• People with a history of serious brain or neurological conditions, including head trauma, loss of consciousness, epilepsy, or blood vessel-related brain disease
• People with a history of serious heart conditions, including a prolonged QT interval on a heart tracing or severe irregular heartbeat
• People who are pregnant or breastfeeding
• People with a severe active infection (minor infections such as urinary tract infections or bacterial throat infections are not automatically excluded — confirm with trial site)
• People with an active hepatitis B or hepatitis C infection
• People who have taken steroid medications throughout the body (not inhaled steroids) within the two weeks before screening
• People who have previously received CAR-T cell therapy or any other genetically modified T cell treatment
• People whose kidney or liver function test results fall outside the limits set by the trial (confirm with trial site)
• People with other serious uncontrolled health conditions considered unsuitable for the trial
• People living with HIV
• People in any situation where the trial doctor considers participation may raise safety concerns or affect the reliability of the results

Important: Always verify eligibility with the trial site directly before applying.